In a groundbreaking decision, the FDA has approved Wegovy, originally a weight loss medication, for use as a heart disease prevention medication. This approval comes after a large trial with 17,600 participants demonstrated significant reductions in cardiovascular risk when using Wegovy, a GLP-1 receptor agonist made by Novo Nordisk in Denmark.
Wegovy can now be used to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are overweight or obese. This makes Wegovy the first weight-loss medication approved for preventing cardiovascular events in this patient population.
Experts in the field of weight management and cardiology are praising the FDA’s approval as a landmark decision. They believe that this approval will help reduce bias and stigma around weight-loss medications and pave the way for similar medications to enter the market in the future.
Patients are advised to speak with their healthcare providers about the potential benefits and side effects of using Wegovy. This approval opens up new possibilities for individuals looking to manage their weight while also reducing their risk of cardiovascular events.
“Prone to fits of apathy. Devoted music geek. Troublemaker. Typical analyst. Alcohol practitioner. Food junkie. Passionate tv fan. Web expert.”